ProShare Advisors LLC Purchases New Shares in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV)

ProShare Advisors LLC acquired a new stake in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,906 shares of the specialty pharmaceutical company’s stock, valued at approximately $101,000.

Several other hedge funds also recently bought and sold shares of KALV. Boxer Capital Management LLC bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at $13,467,000. Octagon Capital Advisors LP bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at $11,604,000. Allostery Investments LP bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at $4,058,000. Schroder Investment Management Group grew its position in KalVista Pharmaceuticals by 86.8% in the 4th quarter. Schroder Investment Management Group now owns 805,445 shares of the specialty pharmaceutical company’s stock valued at $6,758,000 after acquiring an additional 374,213 shares during the last quarter. Finally, Walleye Capital LLC bought a new position in KalVista Pharmaceuticals in the 4th quarter valued at $2,268,000.

Insider Transactions at KalVista Pharmaceuticals

In related news, major shareholder Venrock Healthcare Capital Par acquired 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 9th. The shares were bought at an average price of $9.42 per share, with a total value of $235,500.00. Following the completion of the transaction, the insider now directly owns 5,303,985 shares in the company, valued at $49,963,538.70. This trade represents a 0.47% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Benjamin L. Palleiko sold 3,808 shares of the firm’s stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $11.84, for a total value of $45,086.72. Following the sale, the chief executive officer now directly owns 293,367 shares in the company, valued at approximately $3,473,465.28. The trade was a 1.28% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 15,399 shares of company stock valued at $182,054. 10.50% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research report on Tuesday, April 8th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Finally, Jones Trading reissued a “buy” rating and set a $30.00 price target on shares of KalVista Pharmaceuticals in a research report on Wednesday, March 26th. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and an average target price of $24.83.

KalVista Pharmaceuticals Trading Up 3.3%

KALV opened at $13.35 on Wednesday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.30 and a 12-month high of $15.50. The business’s fifty day simple moving average is $11.93 and its 200-day simple moving average is $10.51. The company has a market capitalization of $663.71 million, a price-to-earnings ratio of -3.67 and a beta of 0.05.

KalVista Pharmaceuticals Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).